Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Martin

Showing results (261-270 of 286) with videos related to

Pageof 29
Sort By:
Bioorganic & Medicinal Chemistry Letters|July 16, 2008
Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptaseZachary K Sweeney, Sahaja Acharya, Andrew Briggs, et al.
Knee Surgery, Sports Traumatology, Arthroscopy : Official Journal of the ESSKA|March 30, 2011
Hop tests correlate with IKDC and KOOS at minimum of 2 years after primary ACL reconstructionEmily K Reinke, Kurt P Spindler, Dawn Lorring, et al.
Cancers|July 26, 2020
Understanding and Attitudes toward Cancer Clinical Trials among Patients with a Cancer Diagnosis: National Study through Cancer Trials IrelandCathriona Kearns, Ronan Feighery, John Mc Caffrey, et al.
Nature|February 28, 2012
The translational landscape of mTOR signalling steers cancer initiation and metastasisAndrew C Hsieh, Yi Liu, Merritt P Edlind, et al.
The Lancet. Planetary Health|March 7, 2024
Environmental assessment of diets: overview and guidance on indicator choiceYlva Ran, Christel Cederberg, Malin Jonell, et al.
Acta Oncologica (Stockholm, Sweden)|June 5, 2025
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysisJohn Crown, Alex J Eustace, Denis M Collins, et al.
Cancer Cell|April 9, 2008
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia veraGerlinde Wernig, Michael G Kharas, Rachel Okabe, et al.
Plos One|February 25, 2015
Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypesYen T Duong, Reshma Kassanjee, Alex Welte, et al.
Emerging Infectious Diseases|April 15, 2025
Safety and Immunogenicity of Poultry Vaccine for Protecting Critically Endangered Avian Species against Highly Pathogenic Avian Influenza Virus, United StatesTodd E Katzner, Ashleigh V Blackford, Mary Donahue, et al.
Journal of Medicinal Chemistry|March 4, 2008
Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degenerationMoorthy S S Palanki, Hideo Akiyama, Peter Campochiaro, et al.
Pageof 29

Showing results (261-270 of 286) with videos related to

Sort By:
Pageof 29
Bioorganic & Medicinal Chemistry Letters|July 16, 2008
Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptaseZachary K Sweeney, Sahaja Acharya, Andrew Briggs, et al.
Knee Surgery, Sports Traumatology, Arthroscopy : Official Journal of the ESSKA|March 30, 2011
Hop tests correlate with IKDC and KOOS at minimum of 2 years after primary ACL reconstructionEmily K Reinke, Kurt P Spindler, Dawn Lorring, et al.
Cancers|July 26, 2020
Understanding and Attitudes toward Cancer Clinical Trials among Patients with a Cancer Diagnosis: National Study through Cancer Trials IrelandCathriona Kearns, Ronan Feighery, John Mc Caffrey, et al.
Nature|February 28, 2012
The translational landscape of mTOR signalling steers cancer initiation and metastasisAndrew C Hsieh, Yi Liu, Merritt P Edlind, et al.
The Lancet. Planetary Health|March 7, 2024
Environmental assessment of diets: overview and guidance on indicator choiceYlva Ran, Christel Cederberg, Malin Jonell, et al.
Acta Oncologica (Stockholm, Sweden)|June 5, 2025
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysisJohn Crown, Alex J Eustace, Denis M Collins, et al.
Cancer Cell|April 9, 2008
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia veraGerlinde Wernig, Michael G Kharas, Rachel Okabe, et al.
Plos One|February 25, 2015
Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypesYen T Duong, Reshma Kassanjee, Alex Welte, et al.
Emerging Infectious Diseases|April 15, 2025
Safety and Immunogenicity of Poultry Vaccine for Protecting Critically Endangered Avian Species against Highly Pathogenic Avian Influenza Virus, United StatesTodd E Katzner, Ashleigh V Blackford, Mary Donahue, et al.
Journal of Medicinal Chemistry|March 4, 2008
Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degenerationMoorthy S S Palanki, Hideo Akiyama, Peter Campochiaro, et al.
Pageof 29